Artrya (AYA) AGM 2025 summary

Opening remarks and agenda

• Meeting opened with confirmation of quorum, introductions of board members, CEO, CFO, Company Secretary, auditors, and a CEO presentation on advancing commercialisation and reshaping heart care.

• Chair outlined the meeting format: chair address, formal business, polling on resolutions, and a business update.

Financial performance review

• FY 2025 marked a shift from R&D to commercial operations, with FDA clearances for key software modules and recurring revenue from the SalixⓇ Coronary Anatomy platform.

• $20M capital raised in FY25 and $80M post-year end, providing full funding for U.S. expansion and profitability.

• SaaS business model expected to deliver high margins as revenue grows, with break-even targeted for FY 2027.

• Current burn rate is around AUD 5 million per quarter, with profitability expected as scan volumes increase.

• Commercial agreements include a 5-year contract with Tanner Health and agreements in progress with NGHS and Cone.

Board and executive committee updates

• CEO John Konstantopoulos credited for establishing strong U.S. healthcare relationships and leading U.S. market entry.

• Leadership transition implemented to drive commercialisation and U.S. market entry, with new U.S. President and Clinical Advisory Board established.

• Appointment of Alison Plummer as Customer Success Director, with further U.S. executive hires planned.